Satellos gives early look at Duchenne pill in adults ahead of key data in children

Phase 2Positive

AI Analysis

Summary

Satellos Bioscience released early Phase 2 data for its Duchenne muscular dystrophy pill in adult patients, with a potentially pivotal readout in children expected later in 2026. The company is building clinical evidence for an oral DMD treatment.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Early Phase 2 data in adult patients; pivotal readout in children expected later in 2026

Importance:6/10

Sentiment:

0.40

Duchenne muscular dystrophyoral therapyPhase 2pediatric trialCanadian biotech

Related Companies

$MSCLF

Read the original article

Published by Endpoints News on July 8, 2026 10:30 AM

Read Original